Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Operating Expenses | 17,755 | 16,027 | 4,561 | 4,221 | 3,171 |
| Operating Income | -17,755 | -16,027 | -4,561 | -4,221 | -3,171 |
| Interest Expense | 0 | 1 | 6 | 0 | 0 |
| Other Income | 201 | 2,810 | -289 | -55 | -8,914 |
| Pre-tax Income | -17,554 | -13,217 | -4,856 | -4,277 | -12,085 |
| Income Tax | 231 | N/A | N/A | N/A | N/A |
| Net Income Continuous | -17,785 | -13,443 | -4,856 | -4,277 | -12,085 |
| Net Income | $-17,785 | $-13,443 | $-4,856 | $-4,277 | $-12,085 |
| EPS Basic Total Ops | -21.28 | 28.52 | -5.82 | -5.13 | -70.16 |
| EPS Basic Continuous Ops | -19.40 | 30.86 | -5.82 | -5.13 | -70.16 |
| EPS Diluted Total Ops | -21.28 | 28.52 | -5.82 | -5.13 | -70.16 |
| EPS Diluted Continuous Ops | -19.40 | 30.86 | -5.82 | -5.13 | -70.16 |
| EPS Diluted Before Non-Recurring Items | N/A | -18.58 | -5.49 | -4.94 | -16.81 |
| EBITDA(a) | $-17,731 | $-15,982 | $-4,556 | $-4,208 | $-3,120 |